©The Author(s) 2025.
World J Clin Oncol. Oct 24, 2025; 16(10): 110466
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110466
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110466
Table 2 Selected phosphoantigens used for in vitro activation or expansion of Vδ2 cells
| Abbrev name | Full name | Relative strength | Source | Stability in aqueous solution | Ref. |
| IPP | Isopentenyl pyrophosphate | Approximately 1000 × weaker than HMBPP | Eucaryotic cells | Stable | Latha et al[63], Vantourout et al[64] |
| HMBPP | (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate | Most potent | Prokaryotic cells | Not very stable | Kilcollins et al[65] |
| BrHPP | Bromohydrin pyrophosphate | Stronger than isopentenyl pyrophosphate, weaker than HMBPP | Synthetic | Stable | Sicard et al[66] |
| MEP | Monoethyl phosphate | Unknown | Prokaryotic cells | Stable | Tanaka et al[67] |
- Citation: Lehman N, Zarobkiewicz M. Expansion strategies for Vδ2 γδT cells in cancer immunotherapy: Activation, cytokines, and culture conditions. World J Clin Oncol 2025; 16(10): 110466
- URL: https://www.wjgnet.com/2218-4333/full/v16/i10/110466.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i10.110466